XPose Therapeutics in the news


June 2021

Abstract at the ASCO (American Society of Clinical Oncology) 2021 Annual Meeting on our “Development of a DNA damage response (DDR) therapeutics platform for oncology".

Read the abstract here.

January 2021

Poster on "Targeting the DNA repair enzyme APE1 in cancer therapy" presented at "The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response".

Read the presentation here.

December 2020

XPose Therapeutics and Accelero Biostructures announce Joint Research Collaboration for the Discovery and Development of Novel Cancer Therapies.

Read the article here.

November 2020

Publication on our DDR/cancer therapeutics efforts "Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response" 

Read the article here.

July 2020

XPose Therapeutics is very excited to receive non-dilutive funding (SBIR Phase I) from the National Cancer Institute of the National Institutes of Health to advance the discovery and development of novel therapeutics targeting DDR in cancer.

Full announcement here.

March 2020

XPose Therapeutics accepted into Spring 2020 session of Berkeley SkyDeck HotDesk (Incubator) program.

January 2020

XPose Therapeutics licences hits from Accelero Biostructures for launching focused therapeutics development for DDR target APE1.

July 2019

XPose Therapeutics ("X-ray Poses" or "XPose") receives support for launch from University of California's QB3.